Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01090362




Registration number
NCT01090362
Ethics application status
Date submitted
18/03/2010
Date registered
19/03/2010
Date last updated
28/04/2021

Titles & IDs
Public title
Global Anticoagulant Registry in the Field
Scientific title
Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Secondary ID [1] 0 0
TRI08888
Universal Trial Number (UTN)
Trial acronym
GARFIELD-AF
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Cohort 1 - Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.

Cohort 2 - Cohort completed with 11,351 patients enrolled from 30 countries

Cohort 3 - Cohort 3 completed with 11,139 patients enrolled globally from 32 countries

Cohort 4 - Cohort 4 completed with 11,2780 patients enrolled from 35 countries.

Cohort 5 - Final cohort completed with 12,186 patients enrolled.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Death
Timepoint [1] 0 0
4 months
Primary outcome [2] 0 0
Death
Timepoint [2] 0 0
8 months
Primary outcome [3] 0 0
Death
Timepoint [3] 0 0
12 months
Primary outcome [4] 0 0
Death
Timepoint [4] 0 0
16 months
Primary outcome [5] 0 0
Death
Timepoint [5] 0 0
20 months
Primary outcome [6] 0 0
Death
Timepoint [6] 0 0
24 months
Primary outcome [7] 0 0
Death
Timepoint [7] 0 0
3 years
Primary outcome [8] 0 0
Death
Timepoint [8] 0 0
4 years
Primary outcome [9] 0 0
Stroke/Systemic embolism (SE)
Timepoint [9] 0 0
4 months
Primary outcome [10] 0 0
Stroke/Systemic embolism (SE)
Timepoint [10] 0 0
8 months
Primary outcome [11] 0 0
Stroke/Systemic embolism (SE)
Timepoint [11] 0 0
12 months
Primary outcome [12] 0 0
Stroke/Systemic embolism (SE)
Timepoint [12] 0 0
16 months
Primary outcome [13] 0 0
Stroke/Systemic embolism (SE)
Timepoint [13] 0 0
20 months
Primary outcome [14] 0 0
Stroke/Systemic embolism (SE)
Timepoint [14] 0 0
24 months
Primary outcome [15] 0 0
Stroke/Systemic embolism (SE)
Timepoint [15] 0 0
3 years
Primary outcome [16] 0 0
Stroke/Systemic embolism (SE)
Timepoint [16] 0 0
4 years
Primary outcome [17] 0 0
Major bleeding
Timepoint [17] 0 0
4 months
Primary outcome [18] 0 0
Major bleeding
Timepoint [18] 0 0
8 months
Primary outcome [19] 0 0
Major bleeding
Timepoint [19] 0 0
12 months
Primary outcome [20] 0 0
Major bleeding
Timepoint [20] 0 0
16 months
Primary outcome [21] 0 0
Major bleeding
Timepoint [21] 0 0
20 months
Primary outcome [22] 0 0
Major bleeding
Timepoint [22] 0 0
24 months
Primary outcome [23] 0 0
Major bleeding
Timepoint [23] 0 0
3 years
Primary outcome [24] 0 0
Major bleeding
Timepoint [24] 0 0
4 years
Secondary outcome [1] 0 0
Cerebrovascular events defined as Stroke
Timepoint [1] 0 0
4 months
Secondary outcome [2] 0 0
Cerebrovascular events defined as Stroke
Timepoint [2] 0 0
8 months
Secondary outcome [3] 0 0
Cerebrovascular events defined as Stroke
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
Cerebrovascular events defined as Stroke
Timepoint [4] 0 0
16 months
Secondary outcome [5] 0 0
Cerebrovascular events defined as Stroke
Timepoint [5] 0 0
20 months
Secondary outcome [6] 0 0
Cerebrovascular events defined as Stroke
Timepoint [6] 0 0
24 months
Secondary outcome [7] 0 0
Cerebrovascular events defined as Stroke
Timepoint [7] 0 0
3 years
Secondary outcome [8] 0 0
Cerebrovascular events defined as Stroke
Timepoint [8] 0 0
4 years
Secondary outcome [9] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [9] 0 0
4 months
Secondary outcome [10] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [10] 0 0
8 months
Secondary outcome [11] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [11] 0 0
12 months
Secondary outcome [12] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [12] 0 0
16 months
Secondary outcome [13] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [13] 0 0
20 months
Secondary outcome [14] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [14] 0 0
24 months
Secondary outcome [15] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [15] 0 0
3 years
Secondary outcome [16] 0 0
Transient Ischemic Attacks (TIA)
Timepoint [16] 0 0
4 years
Secondary outcome [17] 0 0
Acute coronary syndromes
Timepoint [17] 0 0
4 months
Secondary outcome [18] 0 0
Acute coronary syndromes
Timepoint [18] 0 0
8 months
Secondary outcome [19] 0 0
Acute coronary syndromes
Timepoint [19] 0 0
12 months
Secondary outcome [20] 0 0
Acute coronary syndromes
Timepoint [20] 0 0
16 months
Secondary outcome [21] 0 0
Acute coronary syndromes
Timepoint [21] 0 0
20 months
Secondary outcome [22] 0 0
Acute coronary syndromes
Timepoint [22] 0 0
24 months
Secondary outcome [23] 0 0
Acute coronary syndromes
Timepoint [23] 0 0
3 years
Secondary outcome [24] 0 0
Acute coronary syndromes
Timepoint [24] 0 0
4 years
Secondary outcome [25] 0 0
Therapy persistence
Timepoint [25] 0 0
4 months
Secondary outcome [26] 0 0
Therapy persistence
Timepoint [26] 0 0
8 months
Secondary outcome [27] 0 0
Therapy persistence
Timepoint [27] 0 0
12 months
Secondary outcome [28] 0 0
Therapy persistence
Timepoint [28] 0 0
16 months
Secondary outcome [29] 0 0
Therapy persistence
Timepoint [29] 0 0
20 months
Secondary outcome [30] 0 0
Therapy persistence
Timepoint [30] 0 0
24 months
Secondary outcome [31] 0 0
Therapy persistence
Timepoint [31] 0 0
3 years
Secondary outcome [32] 0 0
Therapy persistence
Timepoint [32] 0 0
4 years
Secondary outcome [33] 0 0
Incidences of other clinical events
Timepoint [33] 0 0
4 months
Secondary outcome [34] 0 0
Incidences of other clinical events
Timepoint [34] 0 0
8 months
Secondary outcome [35] 0 0
Incidences of other clinical events
Timepoint [35] 0 0
12 months
Secondary outcome [36] 0 0
Incidences of other clinical events
Timepoint [36] 0 0
16 months
Secondary outcome [37] 0 0
Incidences of other clinical events
Timepoint [37] 0 0
20 months
Secondary outcome [38] 0 0
Incidences of other clinical events
Timepoint [38] 0 0
24 months
Secondary outcome [39] 0 0
Incidences of other clinical events
Timepoint [39] 0 0
3 years
Secondary outcome [40] 0 0
Incidences of other clinical events
Timepoint [40] 0 0
4 years
Secondary outcome [41] 0 0
Bleeding Events
Timepoint [41] 0 0
4 months
Secondary outcome [42] 0 0
Bleeding Events
Timepoint [42] 0 0
8 months
Secondary outcome [43] 0 0
Bleeding Events
Timepoint [43] 0 0
12 months
Secondary outcome [44] 0 0
Bleeding Events
Timepoint [44] 0 0
16 months
Secondary outcome [45] 0 0
Bleeding Events
Timepoint [45] 0 0
20 months
Secondary outcome [46] 0 0
Bleeding Events
Timepoint [46] 0 0
24 months
Secondary outcome [47] 0 0
Bleeding Events
Timepoint [47] 0 0
3 years
Secondary outcome [48] 0 0
Bleeding Events
Timepoint [48] 0 0
4 years
Secondary outcome [49] 0 0
Pulmonary Embolism
Timepoint [49] 0 0
4 months
Secondary outcome [50] 0 0
Pulmonary Embolism
Timepoint [50] 0 0
8 months
Secondary outcome [51] 0 0
Pulmonary Embolism
Timepoint [51] 0 0
12 months
Secondary outcome [52] 0 0
Pulmonary Embolism
Timepoint [52] 0 0
16 months
Secondary outcome [53] 0 0
Pulmonary Embolism
Timepoint [53] 0 0
20 months
Secondary outcome [54] 0 0
Pulmonary Embolism
Timepoint [54] 0 0
24 months
Secondary outcome [55] 0 0
Pulmonary Embolism
Timepoint [55] 0 0
3 years
Secondary outcome [56] 0 0
Pulmonary Embolism
Timepoint [56] 0 0
4 years

Eligibility
Key inclusion criteria
Prospective Cohort

* Written informed consent
* Age 18 years and older
* New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one additional risk factor for stroke and regardless of therapy.

Retrospective validation cohort

* Written informed consent
* Age 18 years and older
* Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least one additional risk factor for stroke and regardless of therapy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* No further follow-up envisaged or possible within enrolling hospital or with associated family practitioner.
* Patients with transient AF secondary to a reversible cause.
* Patients recruited in controlled clinical trials.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/12/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/05/2020
Sample size
Target
Accrual to date
Final
57250
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Massachusetts
Country [2] 0 0
Argentina
State/province [2] 0 0
Tucumán
Country [3] 0 0
Austria
State/province [3] 0 0
Graz
Country [4] 0 0
Belgium
State/province [4] 0 0
Brasschaat
Country [5] 0 0
Brazil
State/province [5] 0 0
São Paulo
Country [6] 0 0
Canada
State/province [6] 0 0
Hamilton
Country [7] 0 0
Chile
State/province [7] 0 0
Santiago
Country [8] 0 0
China
State/province [8] 0 0
Beijing
Country [9] 0 0
Czechia
State/province [9] 0 0
Prague
Country [10] 0 0
Denmark
State/province [10] 0 0
Frederiksberg
Country [11] 0 0
Egypt
State/province [11] 0 0
Cairo
Country [12] 0 0
Finland
State/province [12] 0 0
Tampere
Country [13] 0 0
France
State/province [13] 0 0
Paris
Country [14] 0 0
Germany
State/province [14] 0 0
Berlin
Country [15] 0 0
Hungary
State/province [15] 0 0
Budapest
Country [16] 0 0
India
State/province [16] 0 0
Bangalore
Country [17] 0 0
Italy
State/province [17] 0 0
Perugia
Country [18] 0 0
Japan
State/province [18] 0 0
Osaka
Country [19] 0 0
Korea, Republic of
State/province [19] 0 0
Seoul
Country [20] 0 0
Mexico
State/province [20] 0 0
Monterrey
Country [21] 0 0
Netherlands
State/province [21] 0 0
Maastricht
Country [22] 0 0
Norway
State/province [22] 0 0
Oslo
Country [23] 0 0
Poland
State/province [23] 0 0
Warsaw
Country [24] 0 0
Russian Federation
State/province [24] 0 0
Moscow
Country [25] 0 0
Singapore
State/province [25] 0 0
Singapore
Country [26] 0 0
South Africa
State/province [26] 0 0
Johannesburg
Country [27] 0 0
Spain
State/province [27] 0 0
Barcelona
Country [28] 0 0
Sweden
State/province [28] 0 0
Stockholm
Country [29] 0 0
Switzerland
State/province [29] 0 0
Zurich
Country [30] 0 0
Thailand
State/province [30] 0 0
Bangkok
Country [31] 0 0
Turkey
State/province [31] 0 0
Ankara
Country [32] 0 0
Ukraine
State/province [32] 0 0
Kiev
Country [33] 0 0
United Arab Emirates
State/province [33] 0 0
Abu Dhabi
Country [34] 0 0
United Kingdom
State/province [34] 0 0
Coventry

Funding & Sponsors
Primary sponsor type
Other
Name
Thrombosis Research Institute
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bayer
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
University of Birmingham
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Brigham and Women's Hospital
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Commercial sector/industry
Name [4] 0 0
Quintiles, Inc.
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Advanced Drug and Device Services SAS
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
Apothecaries Clinical Research
Address [6] 0 0
Country [6] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).
Trial website
https://clinicaltrials.gov/study/NCT01090362
Trial related presentations / publications
Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.
Apenteng PN, Murray ET, Holder R, Hobbs FD, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013 Apr 23;13:31. doi: 10.1186/1471-2261-13-31.
Aalbers J. GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry. Cardiovasc J Afr. 2012 Oct;23(9):528. No abstract available.
Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.
Fox KAA, Virdone S, Bassand JP, Camm AJ, Goto S, Goldhaber SZ, Haas S, Kayani G, Koretsune Y, Misselwitz F, Oh S, Piccini JP, Parkhomenko A, Sawhney JPS, Stepinska J, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF investigators*. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. BMJ Open. 2022 Jan 7;12(1):e049933. doi: 10.1136/bmjopen-2021-049933.
Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450.
Cools F, Johnson D, Camm AJ, Bassand JP, Verheugt FWA, Yang S, Tsiatis A, Fitzmaurice DA, Goldhaber SZ, Kayani G, Goto S, Haas S, Misselwitz F, Turpie AGG, Fox KAA, Pieper KS, Kakkar AK; GARFIELD-AF Investigators. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. J Thromb Haemost. 2021 Sep;19(9):2322-2334. doi: 10.1111/jth.15415. Epub 2021 Jul 23.
Fox KAA, Virdone S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Oto A, Misselwitz F, Piccini JP, Dalgaard F, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):214-227. doi: 10.1093/ehjqcco/qcab028.
Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey JY, Steffel J, Stepinska J, Bassand JP, Camm AJ; GARFIELD-AF Investigators. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. Ann Med. 2021 Dec;53(1):485-494. doi: 10.1080/07853890.2021.1893897.
Sayin BY, Al Mahmeed W, Ragy HI, Elbahry A, Virdone S, Kakkar AK, Ersanli M, Oto A. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. Adv Ther. 2021 May;38(5):2391-2405. doi: 10.1007/s12325-021-01670-5. Epub 2021 Mar 27.
Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, Camm AJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AK; GARFIELD-AF Investigators. Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. Am J Med. 2021 Jul;134(7):893-901.e11. doi: 10.1016/j.amjmed.2021.01.017. Epub 2021 Feb 16.
Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AK. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560.
Camm AJ, Fox KAA, Virdone S, Bassand JP, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AK; GARFIELD-AF investigators. Comparative effectiveness of oral anticoagulants in everyday practice. Heart. 2021 May 26;107(12):962-970. doi: 10.1136/heartjnl-2020-318420.
Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Grierson Turpie AG, Antoon Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020 Sep 22;76(12):1425-1436. doi: 10.1016/j.jacc.2020.07.045.
Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Heuzey JL, Sawhney JP, Oh S, Stepinska J, Cate VT, Verheugt FW, Kayani G, Pieper KS, Kakkar AK, Garfield-Af Investigators FT. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021 Jan;17(1):19-38. doi: 10.2217/fca-2020-0014. Epub 2020 Jul 22.
Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. Int J Stroke. 2020 Apr;15(3):308-317. doi: 10.1177/1747493019891516. Epub 2019 Dec 17.
Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators. The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.
Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.
Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.
Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.
Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Allu J, Illingworth L, Pieper KS, Kayani G; GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol. 2019 May;42(5):553-560. doi: 10.1002/clc.23176. Epub 2019 Apr 9.
Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.
Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.
Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart J. 2018 Nov-Dec;70(6):828-835. doi: 10.1016/j.ihj.2018.09.001. Epub 2018 Sep 12.
Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K, Heyse A, De Wolf A, Hollanders G, Boussy T, Anne W, Vercammen J, Faes D, Beutels M, Mairesse G, Purnode P, Blankoff I, Vandergoten P, Capiau L, Allu J, Bassand JP, Kayani G; GARFIELD-AF Investigators. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiol. 2019 Aug;74(4):309-318. doi: 10.1080/00015385.2018.1494089. Epub 2018 Oct 27.
Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018 Jan 25;13(1):e0191592. doi: 10.1371/journal.pone.0191592. eCollection 2018.
Apenteng PN, Gao H, Hobbs FR, Fitzmaurice DA; UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open. 2018 Jan 13;8(1):e018905. doi: 10.1136/bmjopen-2017-018905.
Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J. 2018 Feb 7;39(6):464-473. doi: 10.1093/eurheartj/ehx730.
Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.
Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):27-35. doi: 10.1093/ehjqcco/qcx030.
Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017 Mar 6;7(3):e014579. doi: 10.1136/bmjopen-2016-014579.
Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076. eCollection 2016.
Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.
Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016 Nov 15;223:543-547. doi: 10.1016/j.ijcard.2016.08.236. Epub 2016 Aug 13.
Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016 Oct 7;37(38):2882-2889. doi: 10.1093/eurheartj/ehw233. Epub 2016 Jun 29.
Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Jansky P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. Epub 2015 Feb 24.
Public notes

Contacts
Principal investigator
Name 0 0
Ajay K Kakkar
Address 0 0
Thrombosis Research Institute, London, UK
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01090362